Rigel Pharmaceuticals (RIGL) Return on Sales (2010 - 2026)

Rigel Pharmaceuticals' Return on Sales history runs 16 years deep, the most recent figure standing at 0.0% for Q1 2026.

• On a quarterly basis, Return on Sales changed 0.0% year-over-year to 0.0% in Q1 2026; TTM through Mar 2026 was 0.01%, a 1.0% increase from a year earlier, with the FY2025 full-year figure at 0.01%, up 1.0% from the prior year.
• Return on Sales fell to 0.0% in Q1 2026 per RIGL's latest filing, from 0.04% in the prior quarter.
• Across five years, Return on Sales topped out at 0.04% in Q4 2025 and bottomed at 0.02% in Q1 2022.
• The 5-year median for Return on Sales is 0.0% (2023), against an average of 0.0%.
• Across the five-year window, Return on Sales decreased 2 bps in 2022 and gained 4 bps in 2025, its largest moves.
• Year by year, Return on Sales stood at 0.0% in 2022, then slumped by 99 bps to 0.0% in 2023, then surged by 80918 bps to 0.0% in 2024, then soared by 1442 bps to 0.04% in 2025, then sank by 96 bps to 0.0% in 2026.
• Per Business Quant, the three latest RIGL Return on Sales figures stand at 0.0% (Q1 2026), 0.04% (Q4 2025), and 0.0% (Q3 2025).